⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7446199 | 1.00 | — | — | |
| SCHEMBL65171 | 0.70 | — | — | |
| SCHEMBL2121805 | 0.70 | — | — | |
| SCHEMBL21646359 | 0.69 | TBXAS1 (0.40) | — | |
| SCHEMBL23697848 | 0.69 | TBXAS1 (0.40) | — | |
| SCHEMBL29974816 | 0.69 | ALOX15 (0.48) | — | |
| SCHEMBL28486243 | 0.69 | ALOX15 (0.48) | — | |
| SCHEMBL869469 | 0.68 | — | — | |
| SCHEMBL3262556 | 0.67 | — | — | |
| SCHEMBL13260083 | 0.67 | TBXAS1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 825 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022228399-A1 | TRICYCLIC USP1 INHIBITOR AND USE THEREOF | 山东轩竹医药科技有限公司 | 2022-11-03 | — | — | WO | claimed |
| EP-3129065-B1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | AKAMARA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-3672582-B1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS SINAI MEDICAL CENTER (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12569486-B2 | Calmodulin inhibitors, CHK2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4229055-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | NOVARTIS AG (CH) | 2026-03-04 | — | — | EP | disclosed |
| US-12560609-B2 | Biomarkers predictive of cancer cell response to ML329 or a derivative thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260015316-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250388597-A1 | BIFUNCTIONAL PHOTOCROSSLINKING PROBES FOR COVALENT CAPTURE OF PROTEIN-NUCLEIC ACID COMPLEXES IN CELLS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2025-12-25 | — | — | US | disclosed |
| US-12503526-B2 | Nickel catalysts with single alkali ions for homopolymerization and copolymerization | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250361333-A1 | METHODS FOR PREPARING COPOLYMERS AND FOR THE OXIDATIVE DEGRADATION THEREOF | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-11-27 | — | — | US | disclosed |
| US-20030096856-A1 | Cell proliferation inhibitors | ABBVIE INC. | 2003-05-22 | — | — | US | disclosed |
| WO-2003034997-A2 | MODULATORS OF PHOSPHOINOSITIDE 3-KINASE | ICONIX PHARMACEUTICALS, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| US-6521658-B1 | Cell proliferation inhibitors | ABBOTT LABORATORIES | 2003-02-18 | — | — | US | disclosed |
| EP-1181269-A1 | CELL PROLIFERATION INHIBITORS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000073264-A1 | CELL PROLIFERATION INHIBITORS | ABBOTT LABORATORIES (US) | 2000-12-07 | — | — | WO | disclosed |
| US-4604466-A | INTERMEDIATES FOR BRONCHODILATORS | RIKER LABORATORIES, INC. (US) | 1986-08-05 | — | — | US | disclosed |
| US-4604466-A | INTERMEDIATES FOR BRONCHODILATORS | RIKER LABORATORIES, INC. (US) | 1986-08-05 | — | — | US | disclosed |
| US-4478835-A | BRONCHODILATORS | RIKER LABORATORIES, INC. (US) | 1984-10-23 | — | — | US | disclosed |
| US-4478835-A | BRONCHODILATORS | RIKER LABORATORIES, INC. (US) | 1984-10-23 | — | — | US | disclosed |
| US-4478835-A | BRONCHODILATORS | RIKER LABORATORIES, INC. (US) | 1984-10-23 | — | — | US | disclosed |